Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Respiratory products
Please find a list of our respiratory products below.
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhalation powder)
Trelegy Ellipta (92/55/22 micrograms inhalation powder) is a combination of inhaled corticosteroid, long-acting muscarinic receptor antagonist and long-acting beta2-adrenergic agonist (ICS/LAMA/LABA) and is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA or a combination of a LAMA and a LABA.
Anoro▼ Ellipta (umeclidinium / vilanterol inhalation powder)
Anoro Ellipta (55 micrograms/22 micrograms inhalation powder) is a long-acting muscarinic receptor antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA) and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Incruse▼ Ellipta (umeclidinium inhalation powder)
Incruse Ellipta (55 micrograms inhalation powder) is a long acting muscarinic receptor antagonist and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)
Relvar 184/22 mcg Prescribing information
Relvar 92/22 mcg summary of product characteristics
Asthma
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
- patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.
COPD
Relvar Ellipta (92/22mcg inhalation powder) is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.
Nucala (mepolizumab)
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder.
The pre-filled formulations are not indicated in 6-11 year olds.
Seretide (salmeterol xinafoate / fluticasone propionate)
Seretide 50/100, 50/250, 50/500 Diskus
Prescribing information
Asthma
Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist
or
- patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist
Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.
Seretide 500/50 Diskus
Chronic Obstructive Pulmonary Disease (COPD)
Seretide is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Seretide 25/50, 25/125, 25/250 Evohaler
Prescribing information
Asthma
Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β2 agonist
or
- patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
